Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Retrospective Observational Study Using AI to Integrate Proteomics, Pathology, and Clinical Big Data to Build a Multi-modal Model for Predicting the Effectiveness of HER-2 Targeted ADC Therapy (T-DXd) in HER-2 Positive and Low-expression Advanced Breast Cancer, With External Validation.

NCT07689929 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT07689929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07689929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Retrospective Observational Study Using AI to Integrate Proteomics, Pathology, and Clinical Big Data to Build a Multi-modal Model for Predicting the Effectiveness of HER-2 Targeted ADC Therapy (T-DXd) in HER-2 Positive and Low-expression Advanced Breast Cancer, With External Validation.
Lead sponsor
Zhejiang Cancer Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2028
Enrollment
900 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer